Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers

Colgate-Palmolive

Status and phase

Completed

Phase 4

Conditions

Systemic Inflammatory Markers

Periodontal Disease

Treatments

Drug: Triclosan Containing Toothpaste

Drug: Triclosan Free Toothpaste

Study type

Interventional

Funder types

Industry

Identifiers

NCT02670135

CRO-2014-09-CT-ISR-DB

Details and patient eligibility

About

This is a single center, double blinded, randomized, controlled trial. Qualified subjects will be enrolled and randomized to either one of the two study groups: a) using 0.3% triclosan/copolymer/fluoride dentifrice twice daily - b) using a matching control dentifrice (copolymer/fluoride/no triclosan) twice daily.

Full description

The objective of this study is to comparatively evaluate the effects of Colgate Total® toothpaste with triclosan (commercially sold in Israel) and triclosan-free matching placebo toothpaste on markers of inflammation in the bloodstream and to correlate these findings with periodontal disease status in the oral cavity, as determined by the parameters assessed. Periodontal parameters (periodontal pocket dept (PPD), Clinical Attachment loss (CAL)) will be assessed at baseline and after 2, 6 and 12 months of product use. Peripheral blood samples will be drawn from the subjects at baseline and after 2, 6 and 12 months to evaluate the effects of tooth brushing on systemic inflammatory markers (CRP, PGE2, IL-1β, TNF-α).

Enrollment

303 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subject males or females 18 to 50 years old.
Availability for the 12 months duration of the clinical research study.
Subject able and willing to follow study procedures and instructions.
Subject read, understood and signed an informed consent form.
Subject present with at least 20 natural teeth in the functional dentition (excluding third molars).
Initial probing pocket depth of >4mm in at least one tooth/quadrant.
Good general health.
Subjects willing to disclose information on medication.

Exclusion criteria

Subject with concomitant periodontal therapy 6 months prior to enrollment.
Subject with orthodontic appliances.
Subject chronically treated (i.e. two weeks or more) with any medication known to affect inflammation or periodontal status or within one month of the first examination*.
Subject treated with antibiotics within 3 months prior to enrollment.
Subject necessitating antibiotic prophylaxis.
Subject with active infectious diseases (hepatitis, human immunodeficiency virus or Tuberculosis) or subject is immunocompromised as determined by the Investigator*.
Subject with known allergy to oral care products or ingredients in oral care products.
Subject with gross oral pathology, including widespread caries or chronic neglect, extensive restoration, pre-existing gross plaque and calculus, or soft or hard tissue tumor of the oral cavity (determined by the examiner).
Subject diagnosed with aggressive periodontitis or acute necrotizing ulcerative gingivitis.
Participation in any other clinical study or test panel within the one month prior to entry into the study.
Subject pregnant at point of enrollment.